Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
The Study of Failure
"We need the loser to sort out our own defeats and dreams... failure is not the dark side of the American Dream; it is the foundation of it. (Lichtenstein, Alex. “Always Be Closing.” Labour / Le Travail, vol. 57, 2006, pp. 193–199. JSTOR, JSTOR, www.jstor.org/stable/25149671.)"